StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
28
This year
1
Publishing Date
2024 - 01 - 17
1
2023 - 10 - 11
1
2023 - 08 - 03
1
2023 - 05 - 25
1
2023 - 04 - 10
1
2023 - 04 - 06
1
2023 - 03 - 09
1
2023 - 02 - 07
1
2022 - 12 - 08
1
2022 - 11 - 08
1
2022 - 11 - 02
1
2022 - 09 - 28
1
2022 - 08 - 09
1
2022 - 06 - 23
1
2022 - 05 - 26
1
2022 - 04 - 28
1
2022 - 04 - 06
1
2022 - 04 - 05
1
2022 - 03 - 31
1
2022 - 01 - 31
1
2021 - 12 - 08
1
2021 - 12 - 02
1
2021 - 10 - 06
1
2021 - 09 - 30
1
2021 - 07 - 12
1
2021 - 06 - 29
1
2021 - 05 - 19
1
2021 - 04 - 26
1
Sector
Health technology
28
Tags
100
3
Acquire
1
Acquisition
2
Acquisition corp
1
Als
9
Application
4
Approval
9
Berubicin
24
Biopharma
1
Biotech-bay
1
Ces
5
Change
1
Commercial
1
Companies
2
Company announcement
3
Conference
7
Covid-19
1
Deadline
7
Designation
5
Disease
4
Drug
5
Earnings
6
Europe
2
Events
3
Fast track
3
Fast track designation
2
Fda
12
Fda-approvals
2
Financial
4
Financial results
9
Friedreich's ataxia
2
Friedreich’s ataxia
6
Glioblastoma
13
Global
6
Growth
2
Kidney
4
Lone-star-bio
26
Market
2
N/a
48
Offering
4
Ongoing
10
People
3
Pharmaceuticals
21
Potential
14
Presentation
5
Program
3
Regulatory
3
Report
3
Research
5
Results
17
Review
2
Skyclarys
2
Study
7
Submission
3
Switzerland
3
Syndros
4
Therapeutics
2
Treatment
28
Trial
11
Update
6
Entities
3m company
20
Abbott laboratories
55
Abbvie inc.
117
Accuray incorporated
18
Adamis pharmaceuticals corporation
19
Adial pharmaceuticals, inc
18
Alnylam pharmaceuticals, inc.
38
Amgen inc.
46
Arcutis biotherapeutics, inc.
24
Arrowhead pharmaceuticals, inc.
21
Astellas pharma inc
50
Astrazeneca plc
46
Bausch health companies inc.
35
Biogen inc.
41
Bioxcel therapeutics, inc.
19
Boston scientific corporation
21
Brainsway ltd.
39
Bridgebio pharma, inc.
18
Bristol-myers squibb company
93
Cns pharmaceuticals, inc.
26
Coherus biosciences, inc.
28
Ecolab inc.
47
Eli lilly and company
175
Fortress biotech, inc.
27
Gilead sciences, inc.
50
Glaxosmithkline plc
98
Horizon therapeutics public limited company
19
Hoth therapeutics, inc.
24
Incyte corporation
77
Intellia therapeutics, inc.
31
Ionis pharmaceuticals, inc.
19
Jaguar health, inc.
18
Johnson & johnson
195
Karyopharm therapeutics inc.
27
Koninklijke philips n.v.
20
Medicinova, inc.
24
Medtronic plc
44
Merck & company, inc.
62
Moleculin biotech, inc.
27
Novartis ag
137
Novo nordisk a/s
34
Nrx pharmaceuticals inc
19
Orange
84
Pfizer, inc.
73
Reata pharmaceuticals, inc.
28
Regeneron pharmaceuticals, inc.
57
Regenxbio inc.
25
Sanofi
275
Soligenix, inc.
19
Sorrento therapeutics, inc.
37
Takeda pharmaceutical company limited
49
Teleflex incorporated
19
Teva pharmaceutical industries ltd
76
Tg therapeutics, inc.
24
Tonix pharmaceuticals holding corp.
29
Ultragenyx pharmaceutical inc.
25
Verrica pharmaceuticals inc.
23
Vertex pharmaceuticals incorporated
27
Viatris inc.
45
Xylem inc.
35
Symbols
ABT
1
CNSP
19
KNSA
1
MBRX
1
NVS
1
NVSEF
1
PFE
1
RETA
28
SNY
1
SNYNF
1
VRNA
1
XNCR
1
Exchanges
Nasdaq
28
Nyse
1
Crawled Date
2024 - 01 - 17
1
2023 - 10 - 11
1
2023 - 08 - 03
1
2023 - 05 - 25
1
2023 - 04 - 10
1
2023 - 04 - 06
1
2023 - 03 - 09
1
2023 - 02 - 07
1
2022 - 12 - 08
1
2022 - 11 - 08
1
2022 - 11 - 02
1
2022 - 09 - 28
1
2022 - 08 - 09
1
2022 - 06 - 23
1
2022 - 05 - 26
1
2022 - 04 - 28
1
2022 - 04 - 06
1
2022 - 04 - 05
1
2022 - 03 - 31
1
2022 - 01 - 31
1
2021 - 12 - 08
1
2021 - 12 - 02
1
2021 - 10 - 06
1
2021 - 09 - 30
1
2021 - 07 - 12
1
2021 - 06 - 29
1
2021 - 05 - 19
1
2021 - 04 - 26
1
Crawled Time
11:00
2
12:00
2
12:15
1
12:20
1
13:00
4
13:20
2
13:30
1
14:00
2
14:20
2
14:30
1
15:00
2
15:30
1
16:00
3
19:00
1
20:00
1
21:00
1
22:00
1
Source
www.biospace.com
19
www.globenewswire.com
3
www.prnewswire.com
6
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Treatment
entities :
Reata pharmaceuticals, inc.
save search
CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published:
2024-01-17
(Crawled : 14:30)
- biospace.com/
CNSP
A
|
$0.2064
-1.01%
-1.02%
210K
|
Health Technology
|
-71.06%
|
O:
5.82%
H:
7.57%
C:
-7.32%
berubicin
treatment
pharmaceuticals
glioblastoma
study
CNS Pharmaceuticals' (NASDAQ:CNSP) Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Date
Published:
2023-10-11
(Crawled : 13:00)
- biospace.com/
CNSP
A
|
$0.2064
-1.01%
-1.02%
210K
|
Health Technology
|
-80.51%
|
O:
-2.8%
H:
18.26%
C:
13.46%
rapid
berubicin
treatment
ongoing
glioblastoma
study
CNS Pharmaceuticals Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published:
2023-08-03
(Crawled : 12:20)
- biospace.com/
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
3.77%
|
O:
0.07%
H:
0.83%
C:
0.57%
CNSP
A
|
$0.2064
-1.01%
-1.02%
210K
|
Health Technology
|
-90.26%
|
O:
0.93%
H:
3.24%
C:
1.39%
berubicin
update
treatment
ongoing
pharmaceuticals
trial
glioblastoma
study
CNS Pharmaceuticals (NASDAQ:CNSP) Achieves Over 50% Completion of Enrollment in Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published:
2023-05-25
(Crawled : 20:00)
- biospace.com/
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
80.75%
|
O:
-0.18%
H:
0.79%
C:
-2.78%
CNSP
A
|
$0.2064
-1.01%
-1.02%
210K
|
Health Technology
|
-89.52%
|
O:
-4.52%
H:
6.84%
C:
4.74%
berubicin
treatment
pharmaceuticals
glioblastoma
study
Over 100 Patients Now Enrolled in CNS Pharmaceuticals’ (NASDAQ: CNSP) Potentially Pivotal Study Evaluating Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published:
2023-04-10
(Crawled : 16:00)
- biospace.com/
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
83.4%
|
O:
-1.23%
H:
1.81%
C:
1.25%
CNSP
A
|
$0.2064
-1.01%
-1.02%
210K
|
Health Technology
|
-72.2%
|
O:
-4.79%
H:
8.16%
C:
4.9%
berubicin
treatment
100
glioblastoma
study
CNS Pharmaceuticals Receives Approval from Competent Authority and Central Ethics Committee in Italy for Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Published:
2023-04-06
(Crawled : 14:20)
- biospace.com/
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
85.95%
|
O:
0.79%
H:
0.86%
C:
0.6%
CNSP
A
|
$0.2064
-1.01%
-1.02%
210K
|
Health Technology
|
-75.92%
|
O:
53.58%
H:
6.02%
C:
-43.6%
approval
berubicin
treatment
pharmaceuticals
global
trial
CNS Pharmaceuticals Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM with First Patient Enrolled in Switzerland
Published:
2023-03-09
(Crawled : 14:20)
- prnewswire.com
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
105.29%
|
O:
-2.68%
H:
5.52%
C:
3.54%
CNSP
A
|
$0.2064
-1.01%
-1.02%
210K
|
Health Technology
|
-85.82%
|
O:
-2.72%
H:
4.3%
C:
-5.59%
treatment
ongoing
pharmaceuticals
global
trial
berubicin
momentum
switzerland
CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Published:
2023-02-07
(Crawled : 14:00)
- prnewswire.com
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
246.94%
|
O:
0.0%
H:
0.64%
C:
-0.91%
CNSP
A
|
$0.2064
-1.01%
-1.02%
210K
|
Health Technology
|
-91.11%
|
O:
-1.49%
H:
5.19%
C:
-6.49%
treatment
ongoing
pharmaceuticals
global
trial
berubicin
CNS Pharmaceuticals Announces Preliminary Results from Ongoing Potentially Pivotal Trial Evaluating Berubicin for the Treatment of Recurrent Glioblastoma Multiforme (GBM)
Published:
2022-12-08
(Crawled : 15:00)
- biospace.com/
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
356.46%
|
O:
0.34%
H:
1.98%
C:
-1.85%
CNSP
A
|
$0.2064
-1.01%
-1.02%
210K
|
Health Technology
|
-91.2%
|
O:
2.92%
H:
0.03%
C:
-3.66%
treatment
ongoing
pharmaceuticals
trial
berubicin
glioblastoma
Extremely Robust COVID-19 Clinical Trial Pipeline With 420+ Key Companies Expected to Change the Pace of the COVID-19 Treatment
Published:
2022-11-08
(Crawled : 16:00)
- prnewswire.com
XNCR
|
$19.08
0.85%
0.84%
450K
|
Health Technology
|
-29.82%
|
O:
0.3%
H:
12.8%
C:
8.43%
VRNA
|
$16.41
1.3%
1.28%
350K
|
Health Technology
|
28.37%
|
O:
1.35%
H:
2.31%
C:
1.09%
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
393.87%
|
O:
3.15%
H:
18.92%
C:
11.92%
KNSA
4
|
$16.96
-2.86%
-2.95%
390K
|
Health Technology
|
14.57%
|
O:
-0.13%
H:
0.26%
C:
-3.81%
covid-19
treatment
companies
change
expected
trial
CNS Pharmaceuticals Announces Dosing of First Patient in Europe/France in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Published:
2022-11-02
(Crawled : 13:00)
- biospace.com/
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
414.05%
|
O:
-0.72%
H:
4.93%
C:
0.24%
CNSP
A
|
$0.2064
-1.01%
-1.02%
210K
|
Health Technology
|
-95.91%
|
O:
5.88%
H:
15.28%
C:
11.0%
treatment
ongoing
pharmaceuticals
global
trial
berubicin
CNS Pharmaceuticals Announces Activation of First Clinical Trial Sites in Europe for Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Published:
2022-09-28
(Crawled : 13:20)
- prnewswire.com
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
642.61%
|
O:
2.2%
H:
9.44%
C:
6.58%
CNSP
A
|
$0.2064
-1.01%
-1.02%
210K
|
Health Technology
|
-96.34%
|
O:
-4.79%
H:
9.94%
C:
7.79%
treatment
europe
ongoing
pharmaceuticals
global
trial
berubicin
Reata Pharmaceuticals Announces Three Month Extension of the Review Period for New Drug Application for Omaveloxolone for the Treatment of Friedreich’s Ataxia
Published:
2022-08-09
(Crawled : 11:00)
- biospace.com/
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
616.38%
|
O:
-1.21%
H:
0.13%
C:
-10.18%
treatment
drug
extension
application
review
friedreich’s ataxia
CNS Pharmaceuticals Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Published:
2022-06-23
(Crawled : 13:20)
- biospace.com/
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
432.63%
|
O:
-0.09%
H:
3.99%
C:
3.0%
CNSP
A
|
$0.2064
-1.01%
-1.02%
210K
|
Health Technology
|
-97.52%
|
O:
32.07%
H:
1.89%
C:
-24.85%
treatment
fda
ongoing
trial
approval
berubicin
potential
Reata Pharmaceuticals Announces FDA Filing Acceptance and Priority Review Designation for the NDA for Omaveloxolone for the Treatment of Patients with Friedreich’s Ataxia
Published:
2022-05-26
(Crawled : 12:00)
- biospace.com/
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
541.22%
|
O:
3.53%
H:
1.51%
C:
-0.11%
treatment
fda
designation
review
friedreich’s ataxia
CNS Pharmaceuticals Receives Approval from Ethics Committee and Competent Authority in Spain for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published:
2022-04-28
(Crawled : 19:00)
- biospace.com/
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
565.23%
|
O:
2.2%
H:
0.68%
C:
-0.26%
CNSP
A
|
$0.2064
-1.01%
-1.02%
210K
|
Health Technology
|
-36.47%
|
O:
8.65%
H:
0.0%
C:
-6.34%
treatment
approval
berubicin
potential
glioblastoma
CNS Pharmaceuticals Receives Approval from France Ethics Committee and Competent Authority for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published:
2022-04-06
(Crawled : 13:00)
- biospace.com/
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
380.38%
|
O:
-1.09%
H:
1.8%
C:
0.45%
CNSP
A
|
$0.2064
-1.01%
-1.02%
210K
|
Health Technology
|
-45.09%
|
O:
5.16%
H:
7.69%
C:
6.16%
treatment
approval
berubicin
potential
glioblastoma
CNS Pharmaceuticals Receives Approval from Competent Authority of Switzerland for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published:
2022-04-05
(Crawled : 14:00)
- biospace.com/
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
373.0%
|
O:
0.63%
H:
1.09%
C:
-2.15%
CNSP
A
|
$0.2064
-1.01%
-1.02%
210K
|
Health Technology
|
-37.03%
|
O:
0.24%
H:
29.56%
C:
14.4%
treatment
approval
berubicin
switzerland
potential
glioblastoma
Reata Pharmaceuticals Completes Rolling Submission of New Drug Application for Omaveloxolone for the Treatment of Patients with Friedreich’s Ataxia
Published:
2022-03-31
(Crawled : 22:00)
- biospace.com/
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
458.16%
|
O:
2.04%
H:
6.09%
C:
3.97%
treatment
drug
application
submission
friedreich’s ataxia
Reata Pharmaceuticals Initiates Rolling Submission of New Drug Application with U.S. FDA for Omaveloxolone for the Treatment of Patients with Friedreich’s Ataxia
Published:
2022-01-31
(Crawled : 15:30)
- biospace.com/
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
592.21%
|
O:
1.0%
H:
13.68%
C:
11.81%
new drug
treatment
fda
als
application
drug
one
submission
friedreich's ataxia
friedreich’s ataxia
← Previous
1
2
Next →
Gainers vs Losers
56%
44%
Top 10 Gainers
INVO
|
$1.76
131.58%
56.82%
230M
|
Health Technology
SINT
|
$0.0365
59.39%
37.26%
470M
|
Health Technology
WISA
4
|
$9.19
50.66%
33.7%
65M
|
Electronic Technology
EDBL
|
$6.73
47.91%
32.39%
13M
|
GCTK
|
$0.715
36.27%
26.62%
640K
|
Manufacturing
TCON
|
$2.33
36.26%
26.61%
2M
|
Health Technology
TIRX
|
$0.48
6.43%
24.58%
4.8M
|
KZIA
|
$0.38
30.58%
23.42%
300K
|
Health Technology
VNDA
|
$5.23
29.14%
22.56%
24M
|
Health Technology
ATNF
|
$1.91
29.05%
22.51%
310K
|
Your saved searches
Save your searches and get alerts when important news are released.